Core Insights - NRx Pharmaceuticals, Inc. is preparing to launch HOPE Therapeutics clinics in Fall 2025, focusing on treating suicidal depression, PTSD, traumatic brain injury, and cognitive dysfunction through a unique residential program that combines various therapies [1][6] - The company recently raised over $8.8 million from biotechnology investors to support its initiatives, with no variable rate features involved in the offering [3][6] Company Overview - NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics for central nervous system disorders, including suicidal depression and PTSD, utilizing its NMDA platform [5] - The company is advancing neuroplastic drug development, including NRX-100 (intravenous ketamine) and NRX-101 (oral D-cycloserine/lurasidone), with NRX-100 receiving Fast Track Designation and NRX-101 receiving Breakthrough Therapy Designation for specific depression treatments [5][7] HOPE Therapeutics Initiative - HOPE Therapeutics will be the first program in the nation to integrate neuroplastic drugs with established treatments like transcranial magnetic stimulation and hyperbaric oxygen therapy, aiming for a response rate exceeding 90% [3][6] - The program will also include nutritional therapy and outdoor activities, creating a comprehensive treatment environment [1][3] Advisory Board and Leadership - Matthew Rockefeller has joined the advisory board of HOPE Therapeutics, enhancing the initiative's leadership and strategic direction [1][6] - The initiative is supported by prominent figures from leading family offices, emphasizing collaboration and innovation in addressing mental health challenges [2]

NRx CEO presented plans for HOPE Therapeutics rollout in September 2025 and establishment of flagship location in Palm Beach, FL during symposium presentation with leadership from Rockefeller Capital and Matthew Rockefeller.Company has recently raised $8.8 million capital from experienced biotech investors with no warrants, repricing, or other variable rate features.HOPE clinics will combine treatment with neuroplastic drugs including ketamine, transcranial magnetic stimulation, and hyperbaric oxygen to tre ...